ABERA BIOSCIENCE AB (8WK) - Total Assets
Based on the latest financial reports, ABERA BIOSCIENCE AB (8WK) holds total assets worth €31.05 Million EUR (≈ $36.30 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ABERA BIOSCIENCE AB - Total Assets Trend (2022–2025)
This chart illustrates how ABERA BIOSCIENCE AB's total assets have evolved over time, based on quarterly financial data. Also see 8WK company net worth for the company's overall valuation and market capitalisation.
ABERA BIOSCIENCE AB - Asset Composition Analysis
Current Asset Composition (December 2025)
ABERA BIOSCIENCE AB's total assets of €31.05 Million consist of 88.8% current assets and 11.2% non-current assets. Review how much debt does ABERA BIOSCIENCE AB carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 82.2% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.89 Million | 6.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how ABERA BIOSCIENCE AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ABERA BIOSCIENCE AB (8WK) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ABERA BIOSCIENCE AB's current assets represent 88.8% of total assets in 2025, a decrease from 90.4% in 2022.
- Cash Position: Cash and equivalents constituted 82.2% of total assets in 2025, up from 78.9% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 9.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 6.6% of total assets.
ABERA BIOSCIENCE AB Competitors by Total Assets
Key competitors of ABERA BIOSCIENCE AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
ABERA BIOSCIENCE AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.69 | 2.94 | 2.15 |
| Quick Ratio | 3.69 | 2.94 | 2.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €20.36 Million | €5.75 Million | €5.70 Million |
ABERA BIOSCIENCE AB - Advanced Valuation Insights
This section examines the relationship between ABERA BIOSCIENCE AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.97 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | 110.0% |
| Total Assets | €28.57 Million |
| Market Capitalization | $14.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values ABERA BIOSCIENCE AB's assets below their book value (0.50x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ABERA BIOSCIENCE AB's assets grew by 110.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ABERA BIOSCIENCE AB (2022–2025)
The table below shows the annual total assets of ABERA BIOSCIENCE AB from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €28.57 Million ≈ $33.40 Million |
+110.00% |
| 2024-12-31 | €13.60 Million ≈ $15.90 Million |
+45.52% |
| 2023-12-31 | €9.35 Million ≈ $10.93 Million |
-52.24% |
| 2022-12-31 | €19.57 Million ≈ $22.88 Million |
-- |
About ABERA BIOSCIENCE AB
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead va… Read more